Hims and Hers Health’s latest results disappointed investors. Shares dropped 14.6% in premarket trading on Tuesday. The company posted a first-quarter loss, catching analysts off guard. They had expected a profit. Here’s a look at what happened, what the company’s guidance means for the future, and whether the stock’s sharp drop is justified.
The subscriber count rose to 2.6 million at the end of the first quarter of 2026, up 4% from 2.5 million at the end of the first quarter of the previous year.
The main issue is clear. Hims grew by offering compounded versions of GLP-1 weight loss drugs. Big pharmaceutical companies couldn’t meet demand. Now, that shortage has ended. In March, Novo Nordisk settled a patent lawsuit with Hims. The settlement requires Hims to sell only branded Ozempic and Wegovy on its platform. This change has created a revenue gap that Hims is now trying to close.
The company’s outlook was more positive than expected. Hims forecasted second-quarter revenue between $680 million and $700 million. This is higher than the $643 million analysts predicted. It also raised its full-year revenue guidance to $2.8 billion to $3.0 billion. This is up from the previous range of $2.7 billion to $2.9 billion. Wall Street had estimated $2.75 billion for the year. These forecasts do not include any potential revenue from the planned acquisition of Australian telehealth provider Eucalyptus. That deal is expected to close in mid-2026.
Peptides could be the company’s next growth area. The government recently eased rules on about a dozen peptides. They had been banned from compounding pharmacies since 2023. Hims has said it plans to enter the peptide market. This market includes products for weight loss, muscle recovery, skin care, and disease treatment. In late April, Morgan Stanley noted that the stock is caught between weak short-term results and optimism about new business areas. Monday’s earnings report highlighted this tension.
The first-quarter results expose a gap between market enthusiasm and Hims’ performance, casting doubt on the sustainability of the stock’s rally.
Featured CoursesRecent news
Nvidia Shares Slip 1.1%: Why a 3-Day Losing Streak Could Be Good News
Nvidia is heading into its most anticipated earnings report of the year on the back foot, and that may be exactly what the stock needs. Shares fell 1.1% in premarket trading Tuesday, extending a three-day pullback from last Thursday’s closing high of $235.74. For investors watching closely, a lower entry point ahead of Wednesday’s results […]
Alphabet and Blackstone Shares Rise on $5B AI Cloud Joint Venture
Google and Blackstone are joining forces to build a new AI cloud company, and investors in both firms are taking notice. Alphabet shares rose 0.5% and Blackstone gained approximately 1% in premarket trading after the companies announced plans to create a U.S.-based joint venture offering data center capacity and Google’s proprietary Tensor Processing Unit chips […]
Alphabet Shares Rise 1.4% as $5 Trillion Market Cap Comes into View
Alphabet is close to a rare milestone. On Monday, its shares rose 1.4%, bringing the Google parent company within about 2% of a $5 trillion market value. This comes just 87 trading days after it first closed above $4 trillion in January. Let’s look at what’s fueling this growth and whether its big AI investments […]
Trade with fewer limits
Day trade with fewer limits at fast speed. Buy stocks and ETFs at low fees.